ProKidney Corp.
NASDAQ:PROK · NASDAQ Capital Market
+$0.02 today
Vol 0.56M · Avg 0.96M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.8%
avg -135.9%
ROIC
-53.9%
avg -152.0%
ROA
-20.6%
avg -109.5%
Analysis
ROE is currently the strongest return metric at 6.8% versus its period average of -135.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bruce Culleton | Chief Executive Officer & Director | $1.18M | — | 57 | $3.00M | 2.02% |
Todd C. Girolamo | Chief Legal Officer & Secretary | $725,102.00 | — | 61 | $327,713.00 | 0.22% |
James Coulston | Chief Financial Officer | $724,872.00 | — | 49 | $600,000.00 | 0.40% |
Ulrich Ernst | EVice President of Science and Technology | $622,743.00 | — | 64 | $335,000.00 | 0.23% |
Kenneth Locke | Chief Technical Officer | — | — | — | $0.00 | <0.01% |
Darin J. Weber | Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access | — | — | 58 | $400,000.00 | 0.27% |
Carla Poulson | Chief People Officer | — | — | — | — | — |
Emily Butler | Senior Vice President of Biometric | — | — | — | — | — |
Joseph Stavas | SVP of Clinical Affairs | — | — | — | — | — |
Gregory Madison | Chief Commercial Officer | — | — | 59 | — | — |
Richard Williams | Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$1.14M
Net Sentiment
$1.14M
Net selling
Most Active
Pereira Brian JG
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 4 sells worth $1.14M over the last 12 months. That adds up to net selling of $1.14M. Pereira Brian JG was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.53B
Nanobiotix S.A.
NASDAQ:NBTX
$1.81B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.68B
Septerna, Inc.
NASDAQ:SEPN
$1.59B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Savara Inc.
NASDAQ:SVRA
$1.12B
Kura Oncology, Inc.
NASDAQ:KURA
$858.00M
Prime Medicine, Inc.
NASDAQ:PRME
$568.04M
Rezolute, Inc.
NASDAQ:RZLT
$488.68M
Who manages PROK?
ProKidney Corp. (PROK) lists 11 active executives. The top listed executive is Kenneth Locke, Chief Technical Officer.
Are PROK insiders buying or selling?
Recent insider activity shows net buying of $216.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.